Novonesis (Novozymes) B
NSISBC
Rank in Stocks
#1160
Established in January 2024 through the amalgamation of Novozymes A/S and Chr.... Established in January 2024 through the amalgamation of Novozymes A/S and Chr. Hansen, Novonesis now stands as a prominent global leader in biosolutions. The firm's activities encompass the worldwide development and commercialization of industrial enzymes, diverse microorganisms, and vital biopharmaceutical ingredients. Distinctively, its Class B shares are listed independently and actively traded on various European exchanges.
Share Price
$70.10
Last synced: 2026-10-21
Market Cap
$19.48B
Change (1 day)
-4.64%
Change (1 year)
10.57%
Country
DK
Trade Novonesis (Novozymes) B (NSISBC)
Category
Basic Materials
Operating Margin for Novonesis (Novozymes) B (NSISBC)
Operating Margin as of 2026 TTM: 0.00%
According to Novonesis (Novozymes) B latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Novonesis (Novozymes) B from 2026 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 27.10% | - |
GB
|
|
| 0.00% | - |
FR
|
|
| 16.36% | - |
US
|
|
| 17.37% | - |
US
|
|
| -4.71% | - |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.